E7389
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms
Trial Timeline
Sep 1, 2004 → Nov 1, 2006
NCT ID
NCT00097721About E7389
E7389 is a phase 2 stage product being developed by Eisai for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00097721. Target conditions include Breast Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432886 | Phase 1 | Completed |
| NCT00413192 | Phase 2 | Completed |
| NCT00326950 | Phase 1 | Completed |
| NCT00278993 | Phase 2 | Completed |
| NCT00246090 | Phase 2 | Completed |
| NCT00097721 | Phase 2 | Completed |
| NCT00069264 | Phase 1 | Completed |
| NCT00069277 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Neoplasms